Angiogenesis-Related Biomarkers (sFlt-1/PLGF) in the Prediction and Diagnosis of Placental Dysfunction: An Approach for Clinical Integration.
Placental dysfunction is involved in a group of obstetrical conditions including preeclampsia, intrauterine growth restriction, and placental abruption. Their timely and accurate recognition is often a challenge since diagnostic criteria are still based on nonspecific signs and symptoms. The discovering of the role of angiogenic-related factors (sFlt-1/PlGF) in the underlying pathophysiology of placental dysfunction, taking into account that angiogenesis-related biomarkers are not specific to any particular placental insufficiency-related disease, has marked an important step for improving their early diagnosis and prognosis assessment. However, sFlt-1/PlGF has not been yet established as a part of most guidelines. We will review the current evidence on the clinical utility of sFlt-1/PlGF and propose a new protocol for its clinical integration.
Fetal Medicine Unit-Maternal and Child Health and Development Network (SAMID), Department of Obstetrics and Gynaecology, Hospital Universitario "12 de Octubre", Universidad Complutense de Madrid, 28041 Madrid, Spain. iherraizg@gmail.com.
Ignacio
I
Herraiz
Fetal Medicine Unit-Maternal and Child Health and Development Network (SAMID), Department of Obstetrics and Gynaecology, Hospital Universitario "12 de Octubre", Universidad Complutense de Madrid, 28041 Madrid, Spain. elisa.simon87@gmail.com.
Elisa
E
Simón
Fetal Medicine Unit-Maternal and Child Health and Development Network (SAMID), Department of Obstetrics and Gynaecology, Hospital Universitario "12 de Octubre", Universidad Complutense de Madrid, 28041 Madrid, Spain.
Paula Isabel
PI
Gómez-Arriaga
Fetal Medicine Unit-Maternal and Child Health and Development Network (SAMID), Department of Obstetrics and Gynaecology, Hospital Universitario "12 de Octubre", Universidad Complutense de Madrid, 28041 Madrid, Spain. josemoratalla@hotmail.com.
José Manuel
JM
Martínez-Moratalla
Fetal Medicine Unit-Maternal and Child Health and Development Network (SAMID), Department of Obstetrics and Gynaecology, Hospital Universitario "12 de Octubre", Universidad Complutense de Madrid, 28041 Madrid, Spain.
Antonio
A
García-Burguillo
Department of Clinical Biochemistry, Hospital Universitario "12 de Octubre", Universidad Complutense de Madrid, 28041 Madrid, Spain. annaelenalopp@yahoo.es.
Elena Ana López
EA
Jiménez
Fetal Medicine Unit-Maternal and Child Health and Development Network (SAMID), Department of Obstetrics and Gynaecology, Hospital Universitario "12 de Octubre", Universidad Complutense de Madrid, 28041 Madrid, Spain. agalindo@salud.madrid.org.
Alberto
A
Galindo
D000037:Abruptio Placentae / Q000175:diagnosis* / Q000503:physiopathology; D015415:Biomarkers / Q000032:analysis; D005260:Female; D005317:Fetal Growth Retardation / Q000175:diagnosis* / Q000503:physiopathology; D006801:Humans; D009389:Neovascularization, Pathologic / Q000175:diagnosis* / Q000503:physiopathology; D010920:Placenta / Q000098:blood supply* / Q000503:physiopathology; D000072483:Placenta Growth Factor; D011225:Pre-Eclampsia / Q000175:diagnosis* / Q000503:physiopathology; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000032:analysis*; D011379:Prognosis; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000032:analysis*
D015415:Biomarkers; C000608036:PGF protein, human; D011257:Pregnancy Proteins; D000072483:Placenta Growth Factor; C501162:FLT1 protein, human; D040281:Vascular Endothelial Growth Factor Receptor-1
PlGF; angiogenesis; intrauterine growth restriction; placental abruption; placental insufficiency; preeclampsia; sFlt-1